Clinical Trials

1,780 enrolled

Neoplasms, Germ Cell and Embryonal, Teratoma, Carcinoma, Embryonal, Endodermal Sinus Tumor

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

5,951 enrolled

Phase 1 Not yet recruiting

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT07498465 2026-03-27

A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

29 enrolled

Phase 3 Active not recruiting

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03267433 2026-03-23

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

689 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT04166318 2026-03-23

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Phase 2 Active not recruiting

252 enrolled

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Phase 3 Not yet recruiting

342 enrolled

Rhabdomyosarcoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

750 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT04293562 2026-02-24

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Other hematologic neoplasm

1,186 enrolled

Leukemia, Myeloid, Acute

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Phase 2 Recruiting

256 enrolled

Genitourinary

Wilms Tumor

NCT04870944 2026-02-24

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Phase 1/2 Recruiting

63 enrolled

CNSLymphoid

Diffuse Intrinsic Pontine Glioma, Lymphoma

NCT05304585 2026-02-24

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

205 enrolled

Other hematologic neoplasm

Rhabdomyosarcoma, Embryonal

NCT06247787 2026-02-24

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Phase 1 Recruiting

36 enrolled

Leukemia, Myelomonocytic, Juvenile

NCT02981628 2026-02-23

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

80 enrolled 1 FDA

Phase 3 Active not recruiting

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04994132 2026-02-17

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

118 enrolled

Phase 2/3 Active not recruiting

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT06820957 2026-02-17

Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

437 enrolled

Phase 2 Active not recruiting

Sarcoma, Ewing

NCT04203316 2026-01-09

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

1 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Phase 2/3 Not yet recruiting

1,708 enrolled

Phase 3 Active not recruiting

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02176967 2025-12-22

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

621 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT07084558 2025-10-28

TEODOR

Phase NA Recruiting

350 enrolled

Breast

Breast Neoplasms

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Phase 2 Active not recruiting

41 enrolled 13 charts

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT06022939 2025-09-15

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

338 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04315324 2025-08-15

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

Phase 1/2 Recruiting

67 enrolled